These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 32111066)
1. NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview. Pramono AA; Rather GM; Herman H; Lestari K; Bertino JR Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111066 [TBL] [Abstract][Full Text] [Related]
2. Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model. Clausing M; William D; Preussler M; Biedermann J; Grützmann K; Richter S; Buchholz F; Temme A; Schröck E; Klink B Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628596 [TBL] [Abstract][Full Text] [Related]
3. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339 [TBL] [Abstract][Full Text] [Related]
4. SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells. Sociali G; Grozio A; Caffa I; Schuster S; Becherini P; Damonte P; Sturla L; Fresia C; Passalacqua M; Mazzola F; Raffaelli N; Garten A; Kiess W; Cea M; Nencioni A; Bruzzone S FASEB J; 2019 Mar; 33(3):3704-3717. PubMed ID: 30514106 [TBL] [Abstract][Full Text] [Related]
5. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities. Chen H; Wang S; Zhang H; Nice EC; Huang C Expert Rev Anticancer Ther; 2016 Aug; 16(8):827-38. PubMed ID: 27186719 [TBL] [Abstract][Full Text] [Related]
6. Inhibitors of NAD Ghanem MS; Caffa I; Monacelli F; Nencioni A Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396769 [TBL] [Abstract][Full Text] [Related]
7. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma. Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121 [TBL] [Abstract][Full Text] [Related]
8. NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer. Hong SM; Park CW; Kim SW; Nam YJ; Yu JH; Shin JH; Yun CH; Im SH; Kim KT; Sung YC; Choi KY Oncogene; 2016 Jul; 35(27):3544-54. PubMed ID: 26568303 [TBL] [Abstract][Full Text] [Related]
9. NAD+ Kinase as a Therapeutic Target in Cancer. Tedeschi PM; Bansal N; Kerrigan JE; Abali EE; Scotto KW; Bertino JR Clin Cancer Res; 2016 Nov; 22(21):5189-5195. PubMed ID: 27582489 [TBL] [Abstract][Full Text] [Related]
10. In cancer, all roads lead to NADPH. Rather GM; Pramono AA; Szekely Z; Bertino JR; Tedeschi PM Pharmacol Ther; 2021 Oct; 226():107864. PubMed ID: 33894275 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099 [TBL] [Abstract][Full Text] [Related]
12. Advances in NAD-Lowering Agents for Cancer Treatment. Ghanem MS; Monacelli F; Nencioni A Nutrients; 2021 May; 13(5):. PubMed ID: 34068917 [TBL] [Abstract][Full Text] [Related]
13. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling. Chowdhry S; Zanca C; Rajkumar U; Koga T; Diao Y; Raviram R; Liu F; Turner K; Yang H; Brunk E; Bi J; Furnari F; Bafna V; Ren B; Mischel PS Nature; 2019 May; 569(7757):570-575. PubMed ID: 31019297 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents. Lucas S; Soave C; Nabil G; Ahmed ZSO; Chen G; El-Banna HA; Dou QP; Wang J Recent Pat Anticancer Drug Discov; 2017; 12(3):190-207. PubMed ID: 28637419 [TBL] [Abstract][Full Text] [Related]
15. Insight Into Nicotinamide Adenine Dinucleotide Homeostasis as a Targetable Metabolic Pathway in Colorectal Cancer. Colombo G; Gelardi ELM; Balestrero FC; Moro M; Travelli C; Genazzani AA Front Pharmacol; 2021; 12():758320. PubMed ID: 34880756 [TBL] [Abstract][Full Text] [Related]
16. Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening. Pulla VK; Sriram DS; Soni V; Viswanadha S; Sriram D; Yogeeswari P Chem Biol Drug Des; 2015 Oct; 86(4):881-94. PubMed ID: 25850461 [TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening. Takeuchi M; Niimi T; Masumoto M; Orita M; Yokota H; Yamamoto T Biol Pharm Bull; 2014; 37(1):31-6. PubMed ID: 24389478 [TBL] [Abstract][Full Text] [Related]
18. A Versatile Continuous Fluorometric Enzymatic Assay for Targeting Nicotinate Phosphoribosyltransferase. Minazzato G; Marangoni E; Fortunato C; Petrelli R; Cappellacci L; Del Bello F; Sorci L; Gasparrini M; Piacente F; Bruzzone S; Raffaelli N Molecules; 2023 Jan; 28(3):. PubMed ID: 36770640 [TBL] [Abstract][Full Text] [Related]
19. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair. Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103 [TBL] [Abstract][Full Text] [Related]
20. Hepatic NAD Dall M; Penke M; Sulek K; Matz-Soja M; Holst B; Garten A; Kiess W; Treebak JT Mol Cell Endocrinol; 2018 Sep; 473():245-256. PubMed ID: 29408602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]